Search hospitals > Ohio > Cincinnati
TriHealth Cancer Institute-Westside
Claim this profileCincinnati, Ohio 45247
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Adenocarcinoma
Conducts research for Non-Small Cell Lung Cancer
187 reported clinical trials
7 medical researchers
Summary
TriHealth Cancer Institute-Westside is a medical facility located in Cincinnati, Ohio. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. TriHealth Cancer Institute-Westside is involved with conducting 187 clinical trials across 396 conditions. There are 7 research doctors associated with this hospital, such as Richard L. Deming, Shahzad Siddique, Saulius Girnius, and Mehmet S. Copur.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Lung Cancer
Global LeaderStage IV
Stage II
Stage III
Top PIs
Richard L. DemingMercy Medical Center - Des Moines4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
172 reported clinical trials
239 drugs studied
Shahzad SiddiquePenrose-Saint Francis Healthcare4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
111 reported clinical trials
176 drugs studied
Saulius GirniusTriHealth Cancer Institute - Medical Oncology and Hematology Westside2 years of reported clinical research
Studies Multiple Myeloma
Studies Plasma Cell Neoplasms
3 reported clinical trials
9 drugs studied
Mehmet S. CopurBethesda North Hospital12 years of reported clinical research
Studies Breast Cancer
Studies Ovarian Cancer
2 reported clinical trials
8 drugs studied
Clinical Trials running at TriHealth Cancer Institute-Westside
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Bladder Cancer
Bladder Carcinoma
Gastric Cancer
Tumors
Pancreatic Cancer
Adenocarcinoma
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at TriHealth Cancer Institute-Westside?
TriHealth Cancer Institute-Westside is a medical facility located in Cincinnati, Ohio. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. TriHealth Cancer Institute-Westside is involved with conducting 187 clinical trials across 396 conditions. There are 7 research doctors associated with this hospital, such as Richard L. Deming, Shahzad Siddique, Saulius Girnius, and Mehmet S. Copur.